In a remarkable stride toward personalized cancer diagnosis and treatment, scientists have unveiled a novel serum biomarker capable of distinguishing between borderline HER2-expressing and clearly HER2-positive breast cancers from other cancer subtypes. The groundbreaking study, led by López Mujica, Boonkaew, Christensen, and colleagues, presents urokinase plasminogen activator (uPA) as a critical molecular signature, promising to revolutionize the clinical landscape where existing HER2 diagnostics sometimes blur the lines between cancer subtypes. This breakthrough, published in the British Journal of Cancer in May 2026, tackles one of oncology’s persistent challenges: accurately categorizing cancer subtypes for optimal therapeutic intervention.
HER2, or human epidermal growth factor receptor 2, is a well-known oncogene whose amplification or overexpression is associated with aggressive breast cancer phenotypes and a worse prognosis. Current clinical protocols rely heavily on immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) to classify tumors as HER2-positive or negative, guiding targeted therapies such as trastuzumab. However, borderline cases—those with equivocal HER2 expression—pose a diagnostic dilemma with significant clinical ramifications. In these ambiguous scenarios, therapeutic decisions can become uncertain, underscoring the urgency for more precise, minimally invasive biomarkers.
The new research pivots around uPA, a serine protease involved in extracellular matrix degradation and tumor invasion. Previously studied mostly in the context of metastasis, uPA’s serum levels have not been definitively linked to HER2 status until now. This study harnessed advanced quantitative assays to measure circulating uPA protein concentrations across a large panel of breast cancer patients, comparing these with tumor HER2 status confirmed by gold-standard techniques. The results were striking: patients with borderline HER2-expressing and HER2-positive tumors showed distinctly elevated serum uPA levels compared to those with HER2-negative counterparts.
These findings indicate that uPA does more than simply mark tumor invasiveness. It acts as a molecular beacon, reflecting the underlying oncogenic machinery that drives HER2-related tumor biology. By integrating uPA measurement into diagnostic workflows, clinicians could gain a dynamic and systemic readout of tumor aggressiveness, transcending limitations inherent in tissue biopsies. This could dramatically refine patient stratification, eliminating uncertainty for borderline cases and enabling timely initiation of HER2-targeted therapies or alternative intervention strategies.
Moreover, the method’s non-invasive nature offers significant advantages over conventional biopsy-based diagnostics. Blood draws for serum biomarker evaluation are safer, less painful, and can be repeated over time to monitor disease progression or response to treatment. This is particularly valuable in advanced-stage cancer management, where tissue access is challenging. The study’s methodological rigor, including robust controls and cross-validation across multiple institutions, lends strong credibility to the translational potential of uPA assays as companion diagnostics.
The interplay between uPA and HER2 signaling cascades also opens fascinating avenues for mechanistic exploration. Data suggest that HER2 upregulation may induce uPA expression via downstream pathways such as MAPK and PI3K/AKT, creating a feedback loop that potentiates tumor proliferation and invasiveness. Understanding these molecular circuits could facilitate the development of dual-modal therapies that concurrently target receptor tyrosine kinases and proteolytic networks, potentially overcoming resistance mechanisms that compromise current HER2-targeted drugs.
Furthermore, the study’s comprehensive profiling extended beyond breast cancer, including other tumor types with known HER2 expression such as gastric and ovarian cancers. The consistent elevation of serum uPA levels in HER2-positive cohorts regardless of tumor origin underscores the biomarker’s broad applicability. This could standardize HER2 assessment across multiple malignancies, impacting diagnostic algorithms and therapeutic choices far beyond breast oncology.
While the discovery heralds exciting clinical implications, the authors caution that larger longitudinal studies are necessary to validate the prognostic and predictive power of serum uPA. Integrating uPA measurement with emerging multiomic data, including proteomics and genomics, might yield composite biomarker panels that enhance specificity and sensitivity. Additionally, the cost-effectiveness and accessibility of these assays must be evaluated to facilitate widespread adoption within diverse healthcare settings.
This breakthrough dovetails with ongoing trends in precision oncology, where biomarker-driven treatment is rapidly evolving toward more personalized paradigms. The ability to differentiate borderline HER2 statuses with a simple blood test could drastically reduce misclassification rates, minimize overtreatment or undertreatment, and improve patient outcomes. Given the rising global incidence of breast cancer and the substantial clinical burden of HER2 ambiguity, the deployment of serum uPA monitoring could represent a paradigm shift with profound health-economic benefits.
In conclusion, López Mujica et al.’s work propels urokinase plasminogen activator from a niche research molecule into a potent clinical tool poised to transform HER2 cancer diagnostics. As multidisciplinary efforts bridge molecular biology, clinical oncology, and diagnostic innovation, this marker exemplifies how integrated science can overcome long-standing clinical challenges. Moving forward, the oncology community will keenly watch the translation of these findings into validated diagnostic kits, clinical trials, and ultimately, improved standard-of-care practices that personalize treatment and save lives.
The promise of uPA as a serum biomarker for differentiating complex HER2 statuses also beckons further research into its role in tumor microenvironment modulation and immune interactions. Understanding how uPA influences not just cancer cells but also stromal components including fibroblasts and immune infiltrates could broaden therapeutic targeting opportunities. Moreover, its measurable presence in circulation raises prospects for monitoring minimal residual disease and early relapse, areas of intense interest in cancer survivorship.
Notably, these insights arrive at a pivotal moment as novel HER2-targeted agents, including bispecific antibodies and antibody-drug conjugates, are entering clinical practice. Precise HER2 categorization will be critical to identifying patients most likely to benefit from these sophisticated treatments. Serum uPA could serve as a companion diagnostic that streamlines patient selection, thereby maximizing therapeutic efficacy while minimizing unnecessary exposure to toxicities.
As the translational journey unfolds, collaboration between molecular scientists, clinicians, and diagnostic developers will be essential to optimize assay design, interpretive criteria, and clinical protocols. Real-world evidence gathered from prospective cohorts and routine clinical use will refine the biomarker’s utility and uncover further nuances. Importantly, patient engagement and education will be vital to ensure understanding and acceptance of biomarker-based diagnostics as part of individualized cancer care.
In sum, this study underscores the evolving landscape where serum biomarkers complement tissue-based pathology, advancing a more nuanced and clinically actionable understanding of cancer biology. By demystifying the borderline HER2 expression conundrum, serum urokinase plasminogen activator emerges as a compelling beacon guiding precision oncology into its next era.
Subject of Research: Differentiating borderline HER2-expressing and HER2-positive cancers from other subtypes using serum urokinase plasminogen activator.
Article Title: Differentiating borderline HER2-expressing and HER2-positive cancers from other subtypes using serum urokinase plasminogen activator.
Article References:
López Mujica, M.E.J., Boonkaew, S., Christensen, N.L. et al. Differentiating borderline HER2-expressing and HER2-positive cancers from other subtypes using serum urokinase plasminogen activator. Br J Cancer (2026). https://doi.org/10.1038/s41416-026-03471-5
Image Credits: AI Generated
DOI: 10.1038/s41416-026-03471-5
